Magenta Therapeutics, Inc. IPO Research Information

Magenta Therapeutics, Inc. IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Magenta Therapeutics, Inc., and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Magenta Therapeutics, Inc.	MGTA - NYSE	$14.00-$16.00	$15.00	$15.50	6.7 million	6/21/2018
Underwriter(s): J.P. Morgan, Goldman Sachs, Cowen
Co-Manager(s): Wedbush PacGrow
Industry: Health Care
Filing(s): Filed 2018-05-24 Terms Added 2018-06-08 Final Prospectus 2018-06-21

Magenta Therapeutics, Inc. Quote & Chart - Click for current quote - MGTA

About Magenta Therapeutics, Inc. (adapted from Magenta Therapeutics, Inc. prospectus):
They are a clinical-stage biotechnology company developing novel medicines to bring the curative power of bone marrow transplant to more patients.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "MGTA" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.